Current Report Filing (8-k)
May 20 2019 - 8:48AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2019
BIOANALYTICAL
SYSTEMS, INC.
|
(Exact name of registrant as specified in its charter)
|
Indiana
|
|
0-23357
|
|
35-1345024
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
|
|
47906-1382
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act(17CFR240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act(17CFR240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act(17CFR240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Shares
|
|
BASi
|
|
NASDAQ Capital Market
|
The information provided in Item 2.02 and Item 9.01 of this Form 8-K is being furnished and shall not be deemed "filed"
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
Section. The information in Item 2.02 and Item 9.01 of this Form 8-K shall not be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as amended.
Item 2.02. Results
of Operations and Financial Condition.
On May 15, 2019, Bioanalytical
Systems, Inc. issued a press release announcing results for the three and six months of fiscal 2019 ended March 31, 2019. The full
text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01. Financial
Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Bioanalytical
Systems, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
May 20, 2019
|
By:
|
|
/s/
Jill C. Blumhoff
|
|
|
|
|
Jill C. Blumhoff
|
|
|
|
|
Chief Financial Officer,
|
|
|
|
|
Vice President—Finance
|
|
Exhibit Index
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024